Bone and Joint Research Laboratory, Veterans Affairs Health Care System, Salt Lake City, Utah, USA.
J Biomed Mater Res B Appl Biomater. 2010 Feb;92(2):397-408. doi: 10.1002/jbm.b.31528.
Infection remains the main challenge to percutaneous, intramedullary osseointegrated implant technology. The purpose of this investigation was to determine if a broad spectrum antimicrobial, Ceragenin (CSA-13) could prevent pin track infections in a percutaneous tibial pin site in a sheep model.
In 20 sheep, a smooth titanium alloy pin/implant was inserted percutaneously through the medial skin and both cortices of the proximal tibia. In 10 sheep, the pin/skin interface was treated with a CSA-13-embedded foam pad. Ten sheep served as controls receiving an untreated pad. At the end of 24 weeks, or if they presented with clinical signs of infection, the animals were euthanized. Histological stains were processed from soft tissue and bone, and bacterial cultures were taken from tissue, bone, and blood. In addition to clinical signs, sheep were considered infected if at least one tissue culture and/or histologically stained sample was positive.
Compared with the controls, CSA-13 did not prevent pin track infection (p = 0.88). Large gaps around the pin indicated a lack of skin-pin adhesion.
In this application, CSA-13 was not effective in preventing pin track infections. This study suggests that maintaining skin attachment, at the implant surface of osseointegrated implants, is essential as a primary barrier to infection. Local antimicrobial treatments should be considered a secondary barrier to bacterial invasion of the pin/skin interface and deeper tissues.
感染仍然是经皮、髓内骨整合植入技术的主要挑战。本研究旨在确定广谱抗菌剂 Ceragenin(CSA-13)是否可以预防绵羊模型经皮胫骨钉固定部位的钉道感染。
在 20 只绵羊中,通过内侧皮肤和胫骨近端的皮质将光滑的钛合金钉/植入物经皮插入。在 10 只绵羊中,钉/皮肤界面用 CSA-13 嵌入的泡沫垫处理。10 只绵羊作为对照组,使用未处理的垫。24 周后,或者如果它们出现感染的临床症状,动物将被安乐死。从软组织和骨中提取组织学染色,从组织、骨和血液中提取细菌培养物。除了临床症状外,如果至少有一个组织培养物和/或组织学染色样本阳性,绵羊就被认为感染。
与对照组相比,CSA-13 不能预防钉道感染(p=0.88)。钉周围的大间隙表明皮肤与钉的附着不良。
在这种应用中,CSA-13 不能有效预防钉道感染。本研究表明,保持骨整合植入物表面的皮肤附着是防止感染的主要屏障。局部抗菌治疗应被视为钉/皮肤界面和深部组织细菌入侵的次要屏障。